Literature DB >> 15972549

Certain site-directed, nonenzymatically active mutants of the Haemophilus influenzae P4 lipoprotein are able to elicit bactericidal antibodies.

Bruce A Green1, Elizabeth Baranyi, Thomas J Reilly, Arnold L Smith, Gary W Zlotnick.   

Abstract

The Haemophilus influenzae P4 lipoprotein (hel) is a potential component of a nontypeable H. influenzae otitis media vaccine. Since P4 is known to be an enzyme, nonenzymatically active forms of recombinant P4 are required. After site-directed mutagenesis of the hel gene, three of the mutated proteins were shown to be vaccine candidates.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15972549      PMCID： PMC1168610          DOI： 10.1128/IAI.73.7.4454-4457.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  15 in total

1.  Evaluation of pilus vaccines for prevention of experimental otitis media caused by nontypable Haemophilus influenzae.

Authors:  R B Karasic; D J Beste; S C To; W J Doyle; S W Wood; M J Carter; A C To; K Tanpowpong; C D Bluestone; C C Brinton
Journal:  Pediatr Infect Dis J       Date:  1989-01       Impact factor: 2.129

Review 2.  Design and development of pilus vaccines for Haemophilus influenzae diseases.

Authors:  C C Brinton; M J Carter; D B Derber; S Kar; J A Kramarik; A C To; S C To; S W Wood
Journal:  Pediatr Infect Dis J       Date:  1989-01       Impact factor: 2.129

3.  Outer membrane lipoprotein e (P4) of Haemophilus influenzae is a novel phosphomonoesterase.

Authors:  T J Reilly; D L Chance; A L Smith
Journal:  J Bacteriol       Date:  1999-11       Impact factor: 3.490

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  A recombinant non-fatty acylated form of the Hi-PAL (P6) protein of Haemophilus influenzae elicits biologically active antibody against both nontypeable and type b H. influenzae.

Authors:  B A Green; B J Metcalf; T Quinn-Dey; D H Kirkley; S A Quataert; R A Deich
Journal:  Infect Immun       Date:  1990-10       Impact factor: 3.441

6.  A recombinant P4 protein of Haemophilus influenzae induces specific immune responses biologically active against nasopharyngeal colonization in mice after intranasal immunization.

Authors:  Muneki Hotomi; Yorihiko Ikeda; Masaki Suzumoto; Kazuma Yamauchi; Bruce A Green; Gary Zlotnick; Dewan S Billal; Jun Shimada; Keiji Fujihara; Noboru Yamanaka
Journal:  Vaccine       Date:  2005-01-26       Impact factor: 3.641

7.  Contribution of the DDDD motif of H. influenzae e (P4) to phosphomonoesterase activity and heme transport.

Authors:  T J Reilly; B A Green; G W Zlotnick; A L Smith
Journal:  FEBS Lett       Date:  2001-04-06       Impact factor: 4.124

8.  The e (P4) outer membrane protein of Haemophilus influenzae: biologic activity of anti-e serum and cloning and sequencing of the structural gene.

Authors:  B A Green; J E Farley; T Quinn-Dey; R A Deich; G W Zlotnick
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

9.  Identification of a Haemophilus influenzae 5'-nucleotidase protein: cloning of the nucA gene and immunogenicity and characterization of the NucA protein.

Authors:  R J Zagursky; P Ooi; K F Jones; M J Fiske; R P Smith; B A Green
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

10.  Reduction of nasal colonization of nontypeable Haemophilus influenzae following intranasal immunization with rLP4/rLP6/UspA2 proteins combined with aqueous formulation of RC529.

Authors:  Kathryn W Mason; Duzhang Zhu; Catherine A Scheuer; John C McMichael; Gary W Zlotnick; Bruce A Green
Journal:  Vaccine       Date:  2004-09-03       Impact factor: 3.641
View more
  8 in total

1.  Crystal structure and immunogenicity of the class C acid phosphatase from Pasteurella multocida.

Authors:  Harkewal Singh; Thomas J Malinski; Thomas J Reilly; Michael T Henzl; John J Tanner
Journal:  Arch Biochem Biophys       Date:  2011-03-01       Impact factor: 4.013

2.  Crystallization of recombinant Haemophilus influenzae e (P4) acid phosphatase.

Authors:  Zhonghui Ou; Richard L Felts; Thomas J Reilly; Jay C Nix; John J Tanner
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2006-04-21

3.  Cloning, purification and crystallization of Bacillus anthracis class C acid phosphatase.

Authors:  Richard L Felts; Thomas J Reilly; Michael J Calcutt; John J Tanner
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2006-06-30

4.  Recognition of nucleoside monophosphate substrates by Haemophilus influenzae class C acid phosphatase.

Authors:  Harkewal Singh; Jonathan P Schuermann; Thomas J Reilly; Michael J Calcutt; John J Tanner
Journal:  J Mol Biol       Date:  2010-10-08       Impact factor: 5.469

5.  Characterization of a unique class C acid phosphatase from Clostridium perfringens.

Authors:  Thomas J Reilly; Deborah L Chance; Michael J Calcutt; John J Tanner; Richard L Felts; Stephen C Waller; Michael T Henzl; Thomas P Mawhinney; Irene K Ganjam; William H Fales
Journal:  Appl Environ Microbiol       Date:  2009-04-10       Impact factor: 4.792

6.  Expression, purification and crystallization of class C acid phosphatases from Francisella tularensis and Pasteurella multocida.

Authors:  Harkewal Singh; Richard L Felts; Li Ma; Thomas J Malinski; Michael J Calcutt; Thomas J Reilly; John J Tanner
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2009-02-12

7.  Outer membrane protein P4 is not required for virulence in the human challenge model of Haemophilus ducreyi infection.

Authors:  Diane M Janowicz; Beth W Zwickl; Kate R Fortney; Barry P Katz; Margaret E Bauer
Journal:  BMC Microbiol       Date:  2014-06-24       Impact factor: 3.605

Review 8.  Microbial 5'-nucleotidases: their characteristics, roles in cellular metabolism, and possible practical applications.

Authors:  Natalia P Zakataeva
Journal:  Appl Microbiol Biotechnol       Date:  2021-09-27       Impact factor: 4.813
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.